Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas.
Identifieur interne : 001875 ( PubMed/Checkpoint ); précédent : 001874; suivant : 001876Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas.
Auteurs : R K Ramanathan [États-Unis] ; D. Goldstein [Australie] ; R L Korn ; F. Arena [États-Unis] ; M. Moore [Canada] ; S. Siena [Italie] ; L. Teixeira [France] ; J. Tabernero [Espagne] ; J-L Van Laethem [Belgique] ; H. Liu ; D. Mcgovern ; B. Lu ; D D Von Hoff [États-Unis]Source :
- Annals of oncology : official journal of the European Society for Medical Oncology [ 1569-8041 ] ; 2016.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Adénocarcinome (anatomopathologie), Adénocarcinome (imagerie diagnostique), Adénocarcinome (traitement médicamenteux), Albumines (administration et posologie), Calendrier d'administration des médicaments, Désoxycytidine (administration et posologie), Désoxycytidine (analogues et dérivés), Femelle, Humains, Mâle, Métastase tumorale, Paclitaxel (administration et posologie), Protocoles de polychimiothérapie antinéoplasique (administration et posologie), Résultat thérapeutique, Sujet âgé, Sujet âgé de 80 ans ou plus, Survie sans rechute, Tomographie par émission de positons, Tumeurs du pancréas (anatomopathologie), Tumeurs du pancréas (imagerie diagnostique), Tumeurs du pancréas (traitement médicamenteux).
- MESH :
- administration et posologie : Albumines, Désoxycytidine, Paclitaxel, Protocoles de polychimiothérapie antinéoplasique.
- analogues et dérivés : Désoxycytidine.
- anatomopathologie : Adénocarcinome, Tumeurs du pancréas.
- imagerie diagnostique : Adénocarcinome, Tumeurs du pancréas.
- traitement médicamenteux : Adénocarcinome, Tumeurs du pancréas.
- Adulte, Adulte d'âge moyen, Calendrier d'administration des médicaments, Femelle, Humains, Mâle, Métastase tumorale, Résultat thérapeutique, Sujet âgé, Sujet âgé de 80 ans ou plus, Survie sans rechute, Tomographie par émission de positons.
English descriptors
- KwdEn :
- Adenocarcinoma (diagnostic imaging), Adenocarcinoma (drug therapy), Adenocarcinoma (pathology), Adult, Aged, Aged, 80 and over, Albumins (administration & dosage), Antineoplastic Combined Chemotherapy Protocols (administration & dosage), Deoxycytidine (administration & dosage), Deoxycytidine (analogs & derivatives), Disease-Free Survival, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Neoplasm Metastasis, Paclitaxel (administration & dosage), Pancreatic Neoplasms (diagnostic imaging), Pancreatic Neoplasms (drug therapy), Pancreatic Neoplasms (pathology), Positron-Emission Tomography, Treatment Outcome.
- MESH :
- chemical , administration & dosage : Albumins, Deoxycytidine, Paclitaxel.
- administration & dosage : Antineoplastic Combined Chemotherapy Protocols.
- chemical , analogs & derivatives : Deoxycytidine.
- diagnostic imaging : Adenocarcinoma, Pancreatic Neoplasms.
- drug therapy : Adenocarcinoma, Pancreatic Neoplasms.
- pathology : Adenocarcinoma, Pancreatic Neoplasms.
- Adult, Aged, Aged, 80 and over, Disease-Free Survival, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Neoplasm Metastasis, Positron-Emission Tomography, Treatment Outcome.
Abstract
In the phase III MPACT trial, nab-paclitaxel plus gemcitabine (nab-P + Gem) demonstrated superior efficacy versus Gem alone for patients with metastatic pancreatic cancer. We sought to examine the feasibility of positron emission tomography (PET) and to compare metabolic response rates and associated correlations with efficacy in the MPACT trial.
DOI: 10.1093/annonc/mdw020
PubMed: 26802153
Affiliations:
- Australie, Belgique, Canada, Espagne, France, Italie, États-Unis
- Catalogne, Lombardie, Nouvelle-Galles du Sud, Région de Bruxelles-Capitale, Île-de-France
- Barcelone, Bruxelles, Milan, Paris, Sydney
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:26802153Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas.</title><author><name sortKey="Ramanathan, R K" sort="Ramanathan, R K" uniqKey="Ramanathan R" first="R K" last="Ramanathan">R K Ramanathan</name><affiliation wicri:level="1"><nlm:affiliation>Division of Hematology/Oncology, Mayo Clinic, Scottsdale, USA ramanathan.ramesh@mayo.edu.</nlm:affiliation><country wicri:rule="url">États-Unis</country><wicri:regionArea>Division of Hematology/Oncology, Mayo Clinic, Scottsdale</wicri:regionArea><wicri:noRegion>Scottsdale</wicri:noRegion></affiliation></author><author><name sortKey="Goldstein, D" sort="Goldstein, D" uniqKey="Goldstein D" first="D" last="Goldstein">D. Goldstein</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Prince of Wales Hospital, Sydney, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Medical Oncology, Prince of Wales Hospital, Sydney</wicri:regionArea><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation></author><author><name sortKey="Korn, R L" sort="Korn, R L" uniqKey="Korn R" first="R L" last="Korn">R L Korn</name><affiliation><nlm:affiliation>Diagnostic Radiology, Scottsdale Medical Imaging, Ltd, Scottsdale.</nlm:affiliation><wicri:noCountry code="subField">Scottsdale</wicri:noCountry></affiliation></author><author><name sortKey="Arena, F" sort="Arena, F" uniqKey="Arena F" first="F" last="Arena">F. Arena</name><affiliation wicri:level="1"><nlm:affiliation>Hematology/Oncology, NYU Langone Arena Oncology, Lake Success, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Hematology/Oncology, NYU Langone Arena Oncology, Lake Success</wicri:regionArea><wicri:noRegion>Lake Success</wicri:noRegion></affiliation></author><author><name sortKey="Moore, M" sort="Moore, M" uniqKey="Moore M" first="M" last="Moore">M. Moore</name><affiliation wicri:level="1"><nlm:affiliation>Provencial Health Services Authority, BC Cancer Agency, Vancouver, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Provencial Health Services Authority, BC Cancer Agency, Vancouver</wicri:regionArea><wicri:noRegion>Vancouver</wicri:noRegion></affiliation></author><author><name sortKey="Siena, S" sort="Siena, S" uniqKey="Siena S" first="S" last="Siena">S. Siena</name><affiliation wicri:level="3"><nlm:affiliation>Falck Division of Oncology, Department of Oncology and Hematology, Niguarda Cancer Center, Ospedale Niguarda Ca' Granda and Università degli Studi di Millano, Milan, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Falck Division of Oncology, Department of Oncology and Hematology, Niguarda Cancer Center, Ospedale Niguarda Ca' Granda and Università degli Studi di Millano, Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Teixeira, L" sort="Teixeira, L" uniqKey="Teixeira L" first="L" last="Teixeira">L. Teixeira</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Hôpital Saint-Antoine, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Medical Oncology, Hôpital Saint-Antoine, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Tabernero, J" sort="Tabernero, J" uniqKey="Tabernero J" first="J" last="Tabernero">J. Tabernero</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Medical Oncology, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Van Laethem, J L" sort="Van Laethem, J L" uniqKey="Van Laethem J" first="J-L" last="Van Laethem">J-L Van Laethem</name><affiliation wicri:level="3"><nlm:affiliation>University Clinic of Brussels, Hôpital Erasme, Brussels, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>University Clinic of Brussels, Hôpital Erasme, Brussels</wicri:regionArea><placeName><settlement type="city">Bruxelles</settlement><region nuts="2">Région de Bruxelles-Capitale</region></placeName></affiliation></author><author><name sortKey="Liu, H" sort="Liu, H" uniqKey="Liu H" first="H" last="Liu">H. Liu</name><affiliation><nlm:affiliation>Biostatistics and Research and Design, Celgene Corporation, Summit.</nlm:affiliation><wicri:noCountry code="subField">Summit</wicri:noCountry></affiliation></author><author><name sortKey="Mcgovern, D" sort="Mcgovern, D" uniqKey="Mcgovern D" first="D" last="Mcgovern">D. Mcgovern</name><affiliation><nlm:affiliation>Biostatistics and Research and Design, Celgene Corporation, Summit.</nlm:affiliation><wicri:noCountry code="subField">Summit</wicri:noCountry></affiliation></author><author><name sortKey="Lu, B" sort="Lu, B" uniqKey="Lu B" first="B" last="Lu">B. Lu</name><affiliation><nlm:affiliation>Biostatistics and Research and Design, Celgene Corporation, Summit.</nlm:affiliation><wicri:noCountry code="subField">Summit</wicri:noCountry></affiliation></author><author><name sortKey="Von Hoff, D D" sort="Von Hoff, D D" uniqKey="Von Hoff D" first="D D" last="Von Hoff">D D Von Hoff</name><affiliation wicri:level="1"><nlm:affiliation>Clinical Research, Translational Genomics Research Institute and Honor Health, Scottsdale, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Clinical Research, Translational Genomics Research Institute and Honor Health, Scottsdale</wicri:regionArea><wicri:noRegion>Scottsdale</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:26802153</idno><idno type="pmid">26802153</idno><idno type="doi">10.1093/annonc/mdw020</idno><idno type="wicri:Area/PubMed/Corpus">002070</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002070</idno><idno type="wicri:Area/PubMed/Curation">002045</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002045</idno><idno type="wicri:Area/PubMed/Checkpoint">002045</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002045</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas.</title><author><name sortKey="Ramanathan, R K" sort="Ramanathan, R K" uniqKey="Ramanathan R" first="R K" last="Ramanathan">R K Ramanathan</name><affiliation wicri:level="1"><nlm:affiliation>Division of Hematology/Oncology, Mayo Clinic, Scottsdale, USA ramanathan.ramesh@mayo.edu.</nlm:affiliation><country wicri:rule="url">États-Unis</country><wicri:regionArea>Division of Hematology/Oncology, Mayo Clinic, Scottsdale</wicri:regionArea><wicri:noRegion>Scottsdale</wicri:noRegion></affiliation></author><author><name sortKey="Goldstein, D" sort="Goldstein, D" uniqKey="Goldstein D" first="D" last="Goldstein">D. Goldstein</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Prince of Wales Hospital, Sydney, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Medical Oncology, Prince of Wales Hospital, Sydney</wicri:regionArea><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation></author><author><name sortKey="Korn, R L" sort="Korn, R L" uniqKey="Korn R" first="R L" last="Korn">R L Korn</name><affiliation><nlm:affiliation>Diagnostic Radiology, Scottsdale Medical Imaging, Ltd, Scottsdale.</nlm:affiliation><wicri:noCountry code="subField">Scottsdale</wicri:noCountry></affiliation></author><author><name sortKey="Arena, F" sort="Arena, F" uniqKey="Arena F" first="F" last="Arena">F. Arena</name><affiliation wicri:level="1"><nlm:affiliation>Hematology/Oncology, NYU Langone Arena Oncology, Lake Success, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Hematology/Oncology, NYU Langone Arena Oncology, Lake Success</wicri:regionArea><wicri:noRegion>Lake Success</wicri:noRegion></affiliation></author><author><name sortKey="Moore, M" sort="Moore, M" uniqKey="Moore M" first="M" last="Moore">M. Moore</name><affiliation wicri:level="1"><nlm:affiliation>Provencial Health Services Authority, BC Cancer Agency, Vancouver, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Provencial Health Services Authority, BC Cancer Agency, Vancouver</wicri:regionArea><wicri:noRegion>Vancouver</wicri:noRegion></affiliation></author><author><name sortKey="Siena, S" sort="Siena, S" uniqKey="Siena S" first="S" last="Siena">S. Siena</name><affiliation wicri:level="3"><nlm:affiliation>Falck Division of Oncology, Department of Oncology and Hematology, Niguarda Cancer Center, Ospedale Niguarda Ca' Granda and Università degli Studi di Millano, Milan, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Falck Division of Oncology, Department of Oncology and Hematology, Niguarda Cancer Center, Ospedale Niguarda Ca' Granda and Università degli Studi di Millano, Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Teixeira, L" sort="Teixeira, L" uniqKey="Teixeira L" first="L" last="Teixeira">L. Teixeira</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Hôpital Saint-Antoine, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Medical Oncology, Hôpital Saint-Antoine, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Tabernero, J" sort="Tabernero, J" uniqKey="Tabernero J" first="J" last="Tabernero">J. Tabernero</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Medical Oncology, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Van Laethem, J L" sort="Van Laethem, J L" uniqKey="Van Laethem J" first="J-L" last="Van Laethem">J-L Van Laethem</name><affiliation wicri:level="3"><nlm:affiliation>University Clinic of Brussels, Hôpital Erasme, Brussels, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>University Clinic of Brussels, Hôpital Erasme, Brussels</wicri:regionArea><placeName><settlement type="city">Bruxelles</settlement><region nuts="2">Région de Bruxelles-Capitale</region></placeName></affiliation></author><author><name sortKey="Liu, H" sort="Liu, H" uniqKey="Liu H" first="H" last="Liu">H. Liu</name><affiliation><nlm:affiliation>Biostatistics and Research and Design, Celgene Corporation, Summit.</nlm:affiliation><wicri:noCountry code="subField">Summit</wicri:noCountry></affiliation></author><author><name sortKey="Mcgovern, D" sort="Mcgovern, D" uniqKey="Mcgovern D" first="D" last="Mcgovern">D. Mcgovern</name><affiliation><nlm:affiliation>Biostatistics and Research and Design, Celgene Corporation, Summit.</nlm:affiliation><wicri:noCountry code="subField">Summit</wicri:noCountry></affiliation></author><author><name sortKey="Lu, B" sort="Lu, B" uniqKey="Lu B" first="B" last="Lu">B. Lu</name><affiliation><nlm:affiliation>Biostatistics and Research and Design, Celgene Corporation, Summit.</nlm:affiliation><wicri:noCountry code="subField">Summit</wicri:noCountry></affiliation></author><author><name sortKey="Von Hoff, D D" sort="Von Hoff, D D" uniqKey="Von Hoff D" first="D D" last="Von Hoff">D D Von Hoff</name><affiliation wicri:level="1"><nlm:affiliation>Clinical Research, Translational Genomics Research Institute and Honor Health, Scottsdale, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Clinical Research, Translational Genomics Research Institute and Honor Health, Scottsdale</wicri:regionArea><wicri:noRegion>Scottsdale</wicri:noRegion></affiliation></author></analytic><series><title level="j">Annals of oncology : official journal of the European Society for Medical Oncology</title><idno type="eISSN">1569-8041</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adenocarcinoma (diagnostic imaging)</term><term>Adenocarcinoma (drug therapy)</term><term>Adenocarcinoma (pathology)</term><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Albumins (administration & dosage)</term><term>Antineoplastic Combined Chemotherapy Protocols (administration & dosage)</term><term>Deoxycytidine (administration & dosage)</term><term>Deoxycytidine (analogs & derivatives)</term><term>Disease-Free Survival</term><term>Drug Administration Schedule</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Neoplasm Metastasis</term><term>Paclitaxel (administration & dosage)</term><term>Pancreatic Neoplasms (diagnostic imaging)</term><term>Pancreatic Neoplasms (drug therapy)</term><term>Pancreatic Neoplasms (pathology)</term><term>Positron-Emission Tomography</term><term>Treatment Outcome</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Adénocarcinome (anatomopathologie)</term><term>Adénocarcinome (imagerie diagnostique)</term><term>Adénocarcinome (traitement médicamenteux)</term><term>Albumines (administration et posologie)</term><term>Calendrier d'administration des médicaments</term><term>Désoxycytidine (administration et posologie)</term><term>Désoxycytidine (analogues et dérivés)</term><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Métastase tumorale</term><term>Paclitaxel (administration et posologie)</term><term>Protocoles de polychimiothérapie antinéoplasique (administration et posologie)</term><term>Résultat thérapeutique</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Survie sans rechute</term><term>Tomographie par émission de positons</term><term>Tumeurs du pancréas (anatomopathologie)</term><term>Tumeurs du pancréas (imagerie diagnostique)</term><term>Tumeurs du pancréas (traitement médicamenteux)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Albumins</term><term>Deoxycytidine</term><term>Paclitaxel</term></keywords><keywords scheme="MESH" qualifier="administration & dosage" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Albumines</term><term>Désoxycytidine</term><term>Paclitaxel</term><term>Protocoles de polychimiothérapie antinéoplasique</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Deoxycytidine</term></keywords><keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>Désoxycytidine</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Adénocarcinome</term><term>Tumeurs du pancréas</term></keywords><keywords scheme="MESH" qualifier="diagnostic imaging" xml:lang="en"><term>Adenocarcinoma</term><term>Pancreatic Neoplasms</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Adenocarcinoma</term><term>Pancreatic Neoplasms</term></keywords><keywords scheme="MESH" qualifier="imagerie diagnostique" xml:lang="fr"><term>Adénocarcinome</term><term>Tumeurs du pancréas</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Adenocarcinoma</term><term>Pancreatic Neoplasms</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Adénocarcinome</term><term>Tumeurs du pancréas</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Disease-Free Survival</term><term>Drug Administration Schedule</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Neoplasm Metastasis</term><term>Positron-Emission Tomography</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Calendrier d'administration des médicaments</term><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Métastase tumorale</term><term>Résultat thérapeutique</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Survie sans rechute</term><term>Tomographie par émission de positons</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In the phase III MPACT trial, nab-paclitaxel plus gemcitabine (nab-P + Gem) demonstrated superior efficacy versus Gem alone for patients with metastatic pancreatic cancer. We sought to examine the feasibility of positron emission tomography (PET) and to compare metabolic response rates and associated correlations with efficacy in the MPACT trial.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26802153</PMID><DateCreated><Year>2016</Year><Month>03</Month><Day>23</Day></DateCreated><DateCompleted><Year>2016</Year><Month>12</Month><Day>13</Day></DateCompleted><DateRevised><Year>2016</Year><Month>12</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1569-8041</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>4</Issue><PubDate><Year>2016</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Annals of oncology : official journal of the European Society for Medical Oncology</Title><ISOAbbreviation>Ann. Oncol.</ISOAbbreviation></Journal><ArticleTitle>Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas.</ArticleTitle><Pagination><MedlinePgn>648-53</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/annonc/mdw020</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">In the phase III MPACT trial, nab-paclitaxel plus gemcitabine (nab-P + Gem) demonstrated superior efficacy versus Gem alone for patients with metastatic pancreatic cancer. We sought to examine the feasibility of positron emission tomography (PET) and to compare metabolic response rates and associated correlations with efficacy in the MPACT trial.</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">Patients with previously untreated metastatic adenocarcinoma of the pancreas were randomized 1:1 to receive nab-P + Gem or Gem alone. Treatment continued until disease progression by RECIST or unacceptable toxicity.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">PET scans were carried out on the first 257 patients enrolled at PET-equipped centers (PET cohort). Most patients (252 of 257) had ≥2 PET-avid lesions, and median maximum standardized uptake values at baseline were 4.6 and 4.5 in the nab-P + Gem and Gem-alone arms, respectively. In a pooled treatment arm analysis, a metabolic response by PET (best response at any time during study) was associated with longer overall survival (OS) (median 11.3 versus 6.9 months; HR, 0.56; P < 0.001). Efficacy results within each treatment arm appeared better for patients with a metabolic response. The metabolic response rate (best response and week 8 response) was higher for nab-P + Gem (best response: 72% versus 53%, P = 0.002; week 8: 67% versus 51%; P = 0.014). Efficacy in the PET cohort was greater for nab-P + Gem versus Gem alone, including for OS (median 10.5 versus 8.4 months; hazard ratio [HR], 0.71; P = 0.009) and ORR by RECIST (31% versus 11%; P < 0.001).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Pancreatic lesions were PET avid at baseline, and the rate of metabolic response was significantly higher for nab-P + Gem versus Gem alone at week 8 and for best response during study. Having a metabolic response was associated with longer survival, and more patients experienced a metabolic response than a RECIST-defined response.</AbstractText><AbstractText Label="CLINICALTRIALSGOV" NlmCategory="UNASSIGNED">NCT00844649.</AbstractText><CopyrightInformation>© The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ramanathan</LastName><ForeName>R K</ForeName><Initials>RK</Initials><AffiliationInfo><Affiliation>Division of Hematology/Oncology, Mayo Clinic, Scottsdale, USA ramanathan.ramesh@mayo.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldstein</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Prince of Wales Hospital, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Korn</LastName><ForeName>R L</ForeName><Initials>RL</Initials><AffiliationInfo><Affiliation>Diagnostic Radiology, Scottsdale Medical Imaging, Ltd, Scottsdale.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arena</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Hematology/Oncology, NYU Langone Arena Oncology, Lake Success, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moore</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Provencial Health Services Authority, BC Cancer Agency, Vancouver, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siena</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Falck Division of Oncology, Department of Oncology and Hematology, Niguarda Cancer Center, Ospedale Niguarda Ca' Granda and Università degli Studi di Millano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teixeira</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Hôpital Saint-Antoine, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tabernero</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Laethem</LastName><ForeName>J-L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>University Clinic of Brussels, Hôpital Erasme, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>H</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Biostatistics and Research and Design, Celgene Corporation, Summit.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McGovern</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Biostatistics and Research and Design, Celgene Corporation, Summit.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Biostatistics and Research and Design, Celgene Corporation, Summit.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Von Hoff</LastName><ForeName>D D</ForeName><Initials>DD</Initials><AffiliationInfo><Affiliation>Clinical Research, Translational Genomics Research Institute and Honor Health, Scottsdale, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00844649</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>01</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ann Oncol</MedlineTA><NlmUniqueID>9007735</NlmUniqueID><ISSNLinking>0923-7534</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C520255">130-nm albumin-bound paclitaxel</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000418">Albumins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0W860991D6</RegistryNumber><NameOfSubstance UI="D003841">Deoxycytidine</NameOfSubstance></Chemical><Chemical><RegistryNumber>B76N6SBZ8R</RegistryNumber><NameOfSubstance UI="C056507">gemcitabine</NameOfSubstance></Chemical><Chemical><RegistryNumber>P88XT4IS4D</RegistryNumber><NameOfSubstance UI="D017239">Paclitaxel</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Eur J Cancer. 1999 Dec;35(13):1773-82</RefSource><PMID Version="1">10673991</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Natl Cancer Inst. 2015 Feb;107(2). pii: dju413. doi: 10.1093/jnci/dju413</RefSource><PMID Version="1">25638248</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Nucl Med. 1997 Sep;38(9):1344-8</RefSource><PMID Version="1">9293784</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AJR Am J Roentgenol. 2004 Dec;183(6):1619-28</RefSource><PMID Version="1">15547201</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Surg. 2004 Dec;240(6):1027-34; discussion 1035-6</RefSource><PMID Version="1">15570208</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Cancer. 2005 Jul;41(11):1533-41</RefSource><PMID Version="1">15953716</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2005 Aug 15;106(4):1376-81</RefSource><PMID Version="1">15860666</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Nucl Med Mol Imaging. 2006 Mar;33(3):263-9</RefSource><PMID Version="1">16270214</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Oncol (R Coll Radiol). 2007 May;19(4):237-55</RefSource><PMID Version="1">17433969</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 2008 Apr 1;14(7):2012-8</RefSource><PMID Version="1">18381939</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Cancer. 2009 Jan;45(2):228-47</RefSource><PMID Version="1">19097774</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2009 Jan 20;27(3):439-45</RefSource><PMID Version="1">19064982</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2011 Dec 1;29(34):4548-54</RefSource><PMID Version="1">21969517</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Semin Radiat Oncol. 2013 Jan;23(1):10-5</RefSource><PMID Version="1">23207042</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2013 Oct 20;31(30):3764-75</RefSource><PMID Version="1">24043732</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Yonsei Med J. 2013 Nov;54(6):1377-83</RefSource><PMID Version="1">24142641</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2013 Oct 31;369(18):1691-703</RefSource><PMID Version="1">24131140</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Nucl Med. 2004 Mar;45(3):357-65</RefSource><PMID Version="1">15001674</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000230" MajorTopicYN="N">Adenocarcinoma</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000418" MajorTopicYN="N">Albumins</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003841" MajorTopicYN="N">Deoxycytidine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs & derivatives</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009362" MajorTopicYN="N">Neoplasm Metastasis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017239" MajorTopicYN="N">Paclitaxel</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010190" MajorTopicYN="N">Pancreatic Neoplasms</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><OtherID Source="NLM">PMC4803456</OtherID><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">gemcitabine</Keyword><Keyword MajorTopicYN="N">metabolic response</Keyword><Keyword MajorTopicYN="N">nab-paclitaxel</Keyword><Keyword MajorTopicYN="N">pancreatic cancer</Keyword><Keyword MajorTopicYN="N">positron emission tomography</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>11</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>12</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>1</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>1</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26802153</ArticleId><ArticleId IdType="pii">mdw020</ArticleId><ArticleId IdType="doi">10.1093/annonc/mdw020</ArticleId><ArticleId IdType="pmc">PMC4803456</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Australie</li><li>Belgique</li><li>Canada</li><li>Espagne</li><li>France</li><li>Italie</li><li>États-Unis</li></country><region><li>Catalogne</li><li>Lombardie</li><li>Nouvelle-Galles du Sud</li><li>Région de Bruxelles-Capitale</li><li>Île-de-France</li></region><settlement><li>Barcelone</li><li>Bruxelles</li><li>Milan</li><li>Paris</li><li>Sydney</li></settlement></list><tree><noCountry><name sortKey="Korn, R L" sort="Korn, R L" uniqKey="Korn R" first="R L" last="Korn">R L Korn</name><name sortKey="Liu, H" sort="Liu, H" uniqKey="Liu H" first="H" last="Liu">H. Liu</name><name sortKey="Lu, B" sort="Lu, B" uniqKey="Lu B" first="B" last="Lu">B. Lu</name><name sortKey="Mcgovern, D" sort="Mcgovern, D" uniqKey="Mcgovern D" first="D" last="Mcgovern">D. Mcgovern</name></noCountry><country name="États-Unis"><noRegion><name sortKey="Ramanathan, R K" sort="Ramanathan, R K" uniqKey="Ramanathan R" first="R K" last="Ramanathan">R K Ramanathan</name></noRegion><name sortKey="Arena, F" sort="Arena, F" uniqKey="Arena F" first="F" last="Arena">F. Arena</name><name sortKey="Von Hoff, D D" sort="Von Hoff, D D" uniqKey="Von Hoff D" first="D D" last="Von Hoff">D D Von Hoff</name></country><country name="Australie"><region name="Nouvelle-Galles du Sud"><name sortKey="Goldstein, D" sort="Goldstein, D" uniqKey="Goldstein D" first="D" last="Goldstein">D. Goldstein</name></region></country><country name="Canada"><noRegion><name sortKey="Moore, M" sort="Moore, M" uniqKey="Moore M" first="M" last="Moore">M. Moore</name></noRegion></country><country name="Italie"><region name="Lombardie"><name sortKey="Siena, S" sort="Siena, S" uniqKey="Siena S" first="S" last="Siena">S. Siena</name></region></country><country name="France"><region name="Île-de-France"><name sortKey="Teixeira, L" sort="Teixeira, L" uniqKey="Teixeira L" first="L" last="Teixeira">L. Teixeira</name></region></country><country name="Espagne"><region name="Catalogne"><name sortKey="Tabernero, J" sort="Tabernero, J" uniqKey="Tabernero J" first="J" last="Tabernero">J. Tabernero</name></region></country><country name="Belgique"><region name="Région de Bruxelles-Capitale"><name sortKey="Van Laethem, J L" sort="Van Laethem, J L" uniqKey="Van Laethem J" first="J-L" last="Van Laethem">J-L Van Laethem</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001875 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 001875 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:26802153
|texte= Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:26802153" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |